Chennai, August 2026: Syncom Formulations (India) Limited (BSE: 524470 | NSE: SYNCOMF), a
WHO-GMP and ISO 9001:2015 certified pharmaceutical company, reported strong financial
results for the quarter ended 30 June 2026, with healthy revenue growth and significant
improvement in profitability.
On a consolidated basis, total income for Q1 FY2026-27 rose 8% to ₹133.36 crore, compared
with ₹122.94 crore in the corresponding quarter last year. Revenue from operations increased
nearly 7% to ₹125.53 crore from ₹116.90 crore. Profit before tax grew 59% to ₹32.25 crore
from ₹20.29 crore, while profit after tax rose approximately 58% to ₹24.85 crore from ₹15.75
crore. Earnings per share improved to ₹0.26 from ₹0.17.
The Board of Directors has recommended a final dividend of ₹0.10 per equity share of ₹1 face
value for FY2025-26, subject to shareholders’ approval at the forthcoming Annual General
Meeting.
Commenting on the performance, Mr. Ankit Kedarmal Bankda, Chairman & Whole-time
Director, said, “This quarter reflects the strength of the foundation we have built through
quality manufacturing, an ethical prescription-led model and the trust of the medical
community. Our focus remains on responsible, sustainable growth and making quality
medicines accessible.”
Syncom operates six specialised domestic divisions supported by over 1,000 medical
representatives across India, with a strong presence in gynaecology, fertility, gastroenterology,
critical care and veterinary medicine. The company exports to more than 15 countries and
holds registrations with over 10 international regulatory authorities.
Its WHO-GMP-approved manufacturing facility in Pithampur, Madhya Pradesh, produces
tablets, capsules, liquid orals, injectables, ophthalmics and topical preparations.
